Janssen Pharmaceutical Co., a subsidiary of Johnson & Johnson, earned FDA approval Wednesday for its prostate cancer drug, Erleada.
Here are three things to know.
1. The agency approved Erleada to treat nonmetastatic prostate cancer that does not respond to hormone therapy.
2. Erleada represents the first FDA-approved treatment for this form of cancer.
3. In a recent clinical trial of 1,207 prostate cancer patients, Erleada reduced the risk of distant metastasis or death by 72 percent compared to a placebo.
4. Erleada's list price will be about $10,920 per month, according to Reuters.